BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28034917)

  • 1. Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
    Mallapareddi A; Ruterbusch J; Reamer E; Eggly S; Xu J
    Fam Pract; 2017 Feb; 34(1):90-97. PubMed ID: 28034917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'What is this active surveillance thing?' Men's and partners' reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option.
    O'Callaghan C; Dryden T; Hyatt A; Brooker J; Burney S; Wootten AC; White A; Frydenberg M; Murphy D; Williams S; Schofield P
    Psychooncology; 2014 Dec; 23(12):1391-8. PubMed ID: 24830805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer.
    Volk RJ; McFall SL; Cantor SB; Byrd TL; Le YC; Kuban DA; Mullen PD
    Psychooncology; 2014 Apr; 23(4):467-72. PubMed ID: 24243777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing Normative Messages About Active Surveillance for Men With Localized Prostate Cancer.
    Volk RJ; Kinsman GT; Le YC; Swank P; Blumenthal-Barby J; McFall SL; Byrd TL; Mullen PD; Cantor SB
    J Health Commun; 2015; 20(9):1014-20. PubMed ID: 26066011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perspective on watchful waiting/active surveillance for localized prostate cancer.
    Xu J; Neale AV; Dailey RK; Eggly S; Schwartz KL
    J Am Board Fam Med; 2012; 25(6):763-70. PubMed ID: 23136314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is "Active Surveillance" an Acceptable Alternative?: A Qualitative Study of Couples' Decision Making about Early-Stage, Localized Prostate Cancer.
    Le YL; McFall SL; Byrd TL; Volk RJ; Cantor SB; Kuban DA; Mullen PD
    Narrat Inq Bioeth; 2016; 6(1):51-61. PubMed ID: 27346824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance.
    Goh AC; Kowalkowski MA; Bailey DE; Kazer MW; Knight SJ; Latini DM
    BJU Int; 2012 Jul; 110(2 Pt 2):E50-6. PubMed ID: 22145791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-making processes among men with low-risk prostate cancer: A survey study.
    Hoffman RM; Van Den Eeden SK; Davis KM; Lobo T; Luta G; Shan J; Aaronson D; Penson DF; Leimpeter AD; Taylor KL
    Psychooncology; 2018 Jan; 27(1):325-332. PubMed ID: 28612468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative insights into how men with low-risk prostate cancer choosing active surveillance negotiate stress and uncertainty.
    Mader EM; Li HH; Lyons KD; Morley CP; Formica MK; Perrapato SD; Irwin BH; Seigne JD; Hyams ES; Mosher T; Hegel MT; Stewart TM
    BMC Urol; 2017 May; 17(1):35. PubMed ID: 28482875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study.
    Chapple A; Ziebland S; Herxheimer A; McPherson A; Shepperd S; Miller R
    BJU Int; 2002 Aug; 90(3):257-64. PubMed ID: 12133062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer.
    Davison BJ; Goldenberg SL
    BJU Int; 2011 Dec; 108(11):1787-93. PubMed ID: 21507187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.
    Tomer A; Rizopoulos D; Nieboer D; Drost FJ; Roobol MJ; Steyerberg EW
    Med Decis Making; 2019 Jul; 39(5):499-508. PubMed ID: 31319751
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.
    Brooks JV; Ellis SD; Morrow E; Kimminau KS; Thrasher JB
    Am J Mens Health; 2018 Sep; 12(5):1719-1727. PubMed ID: 29973123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The experience of adults who choose watchful waiting or active surveillance as an approach to medical treatment: a qualitative systematic review.
    Rittenmeyer L; Huffman D; Alagna M; Moore E
    JBI Database System Rev Implement Rep; 2016 Feb; 14(2):174-255. PubMed ID: 27536798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert panel advocates surveillance for men with low-risk prostate cancer.
    Slomski A
    JAMA; 2012 Jan; 307(2):133. PubMed ID: 22235075
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of physician-patient relationships is associated with the influence of physician treatment recommendations among patients with prostate cancer who chose active surveillance.
    Orom H; Homish DL; Homish GG; Underwood W
    Urol Oncol; 2014 May; 32(4):396-402. PubMed ID: 24332649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.
    Taylor KL; Hoffman RM; Davis KM; Luta G; Leimpeter A; Lobo T; Kelly SP; Shan J; Aaronson D; Tomko CA; Starosta AJ; Hagerman CJ; Van Den Eeden SK
    Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1240-50. PubMed ID: 27257092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.